SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. We are looking for talented, motivated, dynamic employees to join our international ...
SOTIO aims to become a diverse oncology company that develops early stage candidates into marketed immunotherapy products. We seek to add to our portfolio projects that are at advanced preclinical or clinical stages.
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the appointments of two accomplished scientific executives to its leadership team to support the ...
SOTIO’s immunocytokine platform is designed to preferentially activate immune cells in the tumor microenvironment by targeted delivery of a cytokine agonist.
SOTIO is developing SOT106, an ADC against leucine-rich repeat containing 15 (LRRC15). SOT106 is a novel ADC based on SOTIO Biotech’s proprietary antibody and LigaChem Biosciences (former LegoChem) industry-leading ConjuAllTM ADC platform technology.
SOT109 is an ADC candidate targeting cadherin-17 (CDH17), a protein homogenously overexpressed in more than 90% of colorectal cancers (CRC) and abundantly expressed in other GI cancers, including gastric, pancreatic, and esophageal cancers.